Eli Lilly and its subsidiary, Avid Radiopharmaceuticals, have announced that the European Commission has approved Amyvid (Florbetapir (18F)) solution for injection as a diagnostic radiopharmaceutical.
This chapter traces the field’s evolution, in parallel with advances in biomarkers, from the 1984 NINCDS–ADRDA clinical-only criteria to the 2011 NIA–AA biomarker-informed updates, the 2018 research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results